|
2017 Journal Article Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Hertzberg, Mark, Gandhi, Maher K. , Trotman, Judith, Butcher, Belinda, Taper, John, Johnston, Amanda, Gill, Devinder, Ho, Shir-Jing, Cull, Gavin, Fay, Ketih, Chong, Geoff, Grigg, Andrew, Lewis, Ian D. , Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Kannourakis, George, Watson, Anne-Marie, Warburton, Pauline, Wirth, Andrew, Seymour, John F. , Hofman, Michael S. and Hicks, Rodney J. (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102 (2), 356-363. doi: 10.3324/haematol.2016.154039 |
|
2016 Journal Article Dielectrophoretic microfluidic chip enables single-cell measurements for multidrug resistance in heterogeneous acute myeloid leukemia patient samplesKhamenehfar, Avid, Gandhi, Maher K., Chen, Yuchun, Hogge, Donna E. and Li, Paul C. H. (2016). Dielectrophoretic microfluidic chip enables single-cell measurements for multidrug resistance in heterogeneous acute myeloid leukemia patient samples. Analytical Chemistry, 88 (11), 5680-5688. doi: 10.1021/acs.analchem.5b04446 |
|
2016 Journal Article Recent treatment advances in Hodgkin Lymphoma: a concise reviewArulogun, Suzanne, Hertzberg, Mark and Gandhi, Maher K. (2016). Recent treatment advances in Hodgkin Lymphoma: a concise review. Internal Medicine Journal, 46 (12), 1364-1369. doi: 10.1111/imj.13051 |
|
2016 Journal Article The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphomaJones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716 |
|
2016 Journal Article Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?Cui, Qingyan and Gandhi, Maher K. (2016). Whole blood EBV-DNA: a surrogate for immune dysfunction in aggressive lymphoma?. Leukemia and Lymphoma, 57 (3), 507-508. doi: 10.3109/10428194.2015.1087522 |
|
2015 Journal Article Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patientsTaylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2015). Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 30 (10), 1774-1779. doi: 10.1093/ndt/gfv260 |
|
2015 Journal Article Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyKeane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7 |
|
2015 Journal Article Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingKurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169 |
|
2015 Journal Article HLA class I associations with EBV+ post-transplant lymphoproliferative disorderJones, Kimberley, Wockner, Leesa, Thornton, Alycia, Gottlieb, David, Ritchie, David S, Seymour, John F, Kumarasinghe, Gayathri and Gandhi, Maher K (2015). HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 32 (2), 126-130. doi: 10.1016/j.trim.2015.02.005 |
|
2015 Journal Article Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapiesScott, Linda M. and Gandhi, Maher K. (2015). Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 29 (6), 405-415. doi: 10.1016/j.blre.2015.06.002 |
|
2014 Journal Article A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumorsFink, S. E. K., Gandhi, M. K., Nourse, J. P., Keane, C., Jones, K., Crooks, P., Johrens, K., Korfel, A., Schmidt, H., Neumann, S., Tiede, A., Jager, U., Duhrsen, U., Neuhaus, R., Dreyling, M., Borchert, K., Sudhoff, T., Riess, H., Anagnostopoulos, I. and Trappe, R. U. (2014). A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. American Journal of Transplantation, 14 (11), 2577-2587. doi: 10.1111/ajt.12858 |
|
2014 Journal Article A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)Tran, Huyen, Brighton, Tim, Grigg, Andrew, McRae, Simon, Dixon, Joanna, Thurley, Daniel, Gandhi, Maher K., Truman, Matt, Marlton, Paula and Catalano, John (2014). A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study). British Journal of Haematology, 167 (2), 243-251. doi: 10.1111/bjh.13029 |
|
2014 Journal Article In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL)Aya-Bonilla, Carlos, Camilleri, Emily, Haupt, Larisa M., Lea, Rod, Gandhi, Maher K. and Griffiths, Lyn R. (2014). In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin’s lymphoma (NHL). BMC Genomics, 15 (390) 390, 1-12. doi: 10.1186/1471-2164-15-390 |
|
2014 Journal Article The presence of KIR2DS5 confers protection against adult immune thrombocytopeniaSeymour, L. A., Nourse, J. P., Crooks, P., Wockner, L., Bird, R., Tran, H. and Gandhi, M. K. (2014). The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens, 83 (3), 154-160. doi: 10.1111/tan.12295 |
|
2014 Journal Article FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorderZimmermann, Heiner, Weiland, Theresa, Nourse, Jamie P., Gandhi, Maher K., Reinke, Petra, Neuhaus, Ruth, Karbasiyan, Mohsen, Gärtner, Barbara, Anagnostopoulos, Ioannis, Riess, Hanno, Trappe, Ralf and Oertel, Stephan (2014). FCY-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive post-transplant lymphoproliferative disorder. Journal of Immunology Research, 264723 264723, 1-6. doi: 10.1155/2014/264723 |
|
2014 Journal Article A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugArpon, David Rey, Gandhi, Maher K. and Martin, Jennifer H. (2014). A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. British Journal of Clinical Pharmacology, 78 (2), 274-281. doi: 10.1111/bcp.12318 |
|
2014 Journal Article Plasma microRNA are disease response biomarkers in classical Hodgkin lymphomaJones, Kimberley, Nourse, Jamie P., Keane, Colm, Bhatnagar, Atul and Gandhi, Maher K. (2014). Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 20 (1), 253-264. doi: 10.1158/1078-0432.CCR-13-1024 |
|
2013 Journal Article CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapyKeane, Colm, Gill, Devinder, Vari, Frank, Cross, Donna, Griffiths, Lynn and Gandhi, Maher (2013). CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. American Journal of Hematology, 88 (4), 273-276. doi: 10.1002/ajh.23398 |
|
2013 Journal Article Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphomaJones, Kimberley, Vari, Frank, Keane, Colm, Crooks, Pauline, Nourse, Jamie P., Seymour, Louise A., Gottlieb, David, Ritchie, David, Gill, Devinder and Gandhi, Maher K. (2013). Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 19 (3), 731-742. doi: 10.1158/1078-0432.CCR-12-2693 |
|
2013 Journal Article Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern eraEvens A.M., Choquet S., Kroll-Desrosiers A.R., Jagadeesh D., Smith S.M., Morschhauser F., Leblond V., Roy R., Barton B., Gordon L.I., Gandhi M.K., Dierickx D., Schiff D., Habermann T.M. and Trappe R. (2013). Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era. American Journal of Transplantation, 13 (6), 1512-1522. doi: 10.1111/ajt.12211 |
